Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00194129 · ClinicalTrials.gov registry record · Phase 3

Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder

A Phase 3 study, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
Phase 3
Development phase
31
Enrollment target

NCT00194129: Completed Phase 3 study, sponsored by University Hospitals Cleveland Medical Center.

NCT00194129 is a Phase 3 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 31 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00194129, a Phase 3 study, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
31 participants
Enrollment target

Study Summary

This study will determine the efficacy and safety of combination therapy with divalproex and lithium for treating mania in people with rapid cycling bipolar disorder and a substance abuse disorder.

Primary Outcome

A relapse is a return to either a depressive, manic, hypomanic or mixed episode after a period of not have any symptoms.

Interventions

  • DRUG Placebo
  • DRUG Lithium
  • DRUG Divalproex

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 1997-11
Est. Completion 2006-09
Phase Phase 3

What the finished NCT00194129 record still lists

NCT00194129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00194129 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00194129 about?

NCT00194129 is a clinical study titled "Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder". This study will determine the efficacy and safety of combination therapy with divalproex and lithium for treating mania in people with rapid cycling bipolar disorder and a substance abuse disorder.

What is the current status of trial NCT00194129?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 1997-11. Estimated completion is 2006-09.

What interventions are being tested in trial NCT00194129?

The interventions under investigation include: Placebo (DRUG), Lithium (DRUG), Divalproex (DRUG).

Who is sponsoring clinical trial NCT00194129?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00194129's enrollment target sits among peer trials

31 1914th of 2000 higher than 84 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00194129, the US trial registry maintained by the National Library of Medicine. NCT00194129 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.